Apatinib is a novel selective VEGFR-2 inhibitor that inhibits the proliferative ability of thyroid carcinoma and squamous cell carcinoma in vivo and vitro and has been identified in multiple studies.281,282 In a tumor xenograft model, mice benefited from either apatinib alone or apatinib in combination with cytotoxic drugs.283 Tumor angiogenesis was also suppressed after apatinib treatment. This evidence concerns the gene KDR and thyroid gland carcinoma.